| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
70,682 |
44,318 |
$2.56M |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
31,131 |
26,733 |
$1.18M |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
11,396 |
11,057 |
$856K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
50,448 |
22,323 |
$655K |
| S8301 |
Infection control supplies, not otherwise specified |
35,833 |
24,898 |
$551K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
6,613 |
6,111 |
$490K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
5,176 |
5,085 |
$414K |
| G0315 |
Immunization counseling by a physician or other qualified health care professional for covid-19, ages under 21, 5-15 mins time (this code is used for the medicaid early and periodic screening, diagnostic, and treatment benefit (epsdt) |
13,842 |
12,952 |
$389K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
28,196 |
24,782 |
$371K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
29,463 |
11,289 |
$315K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
5,417 |
5,164 |
$270K |
| 99429 |
|
8,543 |
8,387 |
$260K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
2,490 |
2,430 |
$197K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
2,720 |
2,657 |
$157K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
14,205 |
11,701 |
$103K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
1,158 |
1,141 |
$93K |
| 87634 |
|
1,559 |
1,483 |
$88K |
| 99381 |
|
940 |
917 |
$75K |
| 99382 |
|
711 |
703 |
$65K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,884 |
1,800 |
$49K |
| 99383 |
|
539 |
529 |
$49K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
4,368 |
2,989 |
$47K |
| 87807 |
|
3,410 |
3,116 |
$35K |
| 90461 |
|
8,084 |
6,977 |
$27K |
| 92567 |
|
1,934 |
1,871 |
$24K |
| 83655 |
|
2,097 |
2,070 |
$20K |
| 99050 |
|
1,669 |
1,390 |
$17K |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
1,252 |
1,208 |
$16K |
| 99051 |
|
11,192 |
8,532 |
$12K |
| 99000 |
|
1,230 |
1,165 |
$10K |
| 99384 |
|
88 |
87 |
$9K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
183 |
177 |
$8K |
| 99463 |
|
66 |
66 |
$7K |
| 99460 |
|
66 |
65 |
$5K |
| 0071A |
|
132 |
132 |
$5K |
| 96380 |
|
262 |
252 |
$5K |
| 99238 |
Hospital discharge day management, 30 minutes or less |
62 |
62 |
$4K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
125 |
124 |
$4K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
2,775 |
1,737 |
$3K |
| 0072A |
|
59 |
59 |
$2K |
| 0081A |
|
51 |
51 |
$2K |
| 96160 |
|
1,178 |
1,162 |
$2K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,124 |
1,076 |
$942.76 |
| 0082A |
|
12 |
12 |
$480.00 |
| 90686 |
|
3,510 |
3,474 |
$437.09 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
27 |
27 |
$276.99 |
| 92551 |
|
221 |
216 |
$196.61 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
15 |
15 |
$194.48 |
| 86580 |
|
15 |
15 |
$107.73 |
| 90656 |
|
425 |
425 |
$17.48 |
| 85018 |
|
12 |
12 |
$12.04 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
15 |
14 |
$3.78 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
27 |
27 |
$2.37 |
| 90651 |
|
389 |
383 |
$0.01 |
| 90670 |
|
2,855 |
2,826 |
$0.00 |
| 90648 |
|
4,374 |
4,300 |
$0.00 |
| 90700 |
|
1,107 |
1,088 |
$0.00 |
| 90707 |
|
1,169 |
1,147 |
$0.00 |
| 90710 |
|
889 |
874 |
$0.00 |
| 90734 |
|
130 |
129 |
$0.00 |
| 90633 |
|
2,396 |
2,350 |
$0.00 |
| 91308 |
|
76 |
75 |
$0.00 |
| 90671 |
|
1,745 |
1,702 |
$0.00 |
| 90380 |
|
184 |
169 |
$0.00 |
| 99173 |
|
236 |
229 |
$0.00 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
536 |
397 |
$0.00 |
| 90715 |
|
47 |
47 |
$0.00 |
| 90681 |
|
33 |
32 |
$0.00 |
| 90381 |
|
91 |
88 |
$0.00 |
| 90680 |
|
3,298 |
3,245 |
$0.00 |
| 90620 |
|
27 |
27 |
$0.00 |
| 90716 |
|
1,161 |
1,140 |
$0.00 |
| 90696 |
|
815 |
804 |
$0.00 |
| 90723 |
|
3,163 |
3,114 |
$0.00 |
| 90698 |
|
309 |
304 |
$0.00 |
| 91307 |
|
222 |
206 |
$0.00 |
| 90660 |
|
101 |
101 |
$0.00 |
| 90744 |
|
15 |
15 |
$0.00 |